mutLBSgeneDB |
Gene summary for GLP1R |
Gene summary |
Basic gene Info. | Gene symbol | GLP1R |
Gene name | glucagon-like peptide 1 receptor | |
Synonyms | - | |
Cytomap | UCSC genome browser: 6p21 | |
Type of gene | protein-coding | |
RefGenes | NM_002062.3, | |
Description | GLP-1 receptorGLP-1-RGLP-1R | |
Modification date | 20141207 | |
dbXrefs | MIM : 138032 | |
HGNC : HGNC | ||
Ensembl : ENSG00000112164 | ||
HPRD : 00677 | ||
Vega : OTTHUMG00000014638 | ||
Protein | UniProt: P43220 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_GLP1R | |
BioGPS: 2740 | ||
Pathway | NCI Pathway Interaction Database: GLP1R | |
KEGG: GLP1R | ||
REACTOME: GLP1R | ||
Pathway Commons: GLP1R | ||
Context | iHOP: GLP1R | |
ligand binding site mutation search in PubMed: GLP1R | ||
UCL Cancer Institute: GLP1R | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0007204 | positive regulation of cytosolic calcium ion concentration | 7589461 | GO:0019933 | cAMP-mediated signaling | 7589461 |
Top |
Ligand binding site mutations for GLP1R |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | D122 | D122N | SKCM | 1 | F80 | S79L | SKCM | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for GLP1R |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | D122 | D122N | -0.58358269 | F80 | S79L | -0.5074715 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for GLP1R from PDB |
Top |
Differential gene expression and gene-gene network for GLP1R |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for GLP1R |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0020538 | Hypertension | 2 | Biomarker |
umls:C0020507 | Hyperplasia | 1 | Biomarker |
umls:C0027651 | Neoplasms | 1 | Biomarker |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for GLP1R |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Gene-centered drug-gene interaction network |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Approved | DB00040 | Glucagon recombinant | Biotech | |
Approved|investigational | DB01276 | Exenatide | Biotech | |
Investigational | DB05162 | GSK716155 | Small molecule | |
Approved | DB06655 | Liraglutide | Biotech | |
Approved | DB09043 | Albiglutide | Biotech | |
Approved | DB09045 | Dulaglutide | Biotech |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of GLP1R go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 10M | N-DECYL-BETA-D-THIOMALTOSIDE | 3iol | A | D122 | 10M | N-DECYL-BETA-D-THIOMALTOSIDE | 3c59 | A | F80 | 10M | N-DECYL-BETA-D-THIOMALTOSIDE | 3c5t | A | F80 |
Top |
Conservation information for LBS of GLP1R |
Multiple alignments for P43220 in multiple species |
LBS | AA sequence | # species | Species | A28 | PRPQGATVSLW | 1 | Homo sapiens | A28 | PRPQGTTVSLS | 1 | Mus musculus | A28 | PRPQGATVSLS | 1 | Rattus norvegicus | D122 | SLPWRDLSECE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E127 | DLSECEESKRG | 2 | Homo sapiens, Mus musculus | E127 | DLSECEESKQG | 1 | Rattus norvegicus | E128 | LSECEESKRGE | 2 | Homo sapiens, Mus musculus | E128 | LSECEESKQGE | 1 | Rattus norvegicus | E34 | TVSLSETVQKW | 2 | Mus musculus, Rattus norvegicus | E34 | TVSLWETVQKW | 1 | Homo sapiens | E68 | NRTFDDYACWP | 2 | Mus musculus, Rattus norvegicus | E68 | NRTFDEYACWP | 1 | Homo sapiens | F80 | GPPGSFVNVSC | 2 | Mus musculus, Rattus norvegicus | F80 | GEPGSFVNVSC | 1 | Homo sapiens | H99 | SVLQGHVYRFC | 2 | Mus musculus, Rattus norvegicus | H99 | SVPQGHVYRFC | 1 | Homo sapiens | L111 | AEGLWLQKDNS | 1 | Homo sapiens | L111 | AEGLWLHKDNS | 1 | Mus musculus | L111 | AEGIWLHKDNS | 1 | Rattus norvegicus | L123 | LPWRDLSECEE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | L32 | GATVSLWETVQ | 1 | Homo sapiens | L32 | GTTVSLSETVQ | 1 | Mus musculus | L32 | GATVSLSETVQ | 1 | Rattus norvegicus | L89 | SCPWYLPWASS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | N82 | PGSFVNVSCPW | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | P90 | CPWYLPWASSV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | R121 | SSLPWRDLSEC | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | S31 | QGATVSLWETV | 1 | Homo sapiens | S31 | QGTTVSLSETV | 1 | Mus musculus | S31 | QGATVSLSETV | 1 | Rattus norvegicus | T29 | RPQGATVSLWE | 1 | Homo sapiens | T29 | RPQGTTVSLSE | 1 | Mus musculus | T29 | RPQGATVSLSE | 1 | Rattus norvegicus | T35 | VSLSETVQKWR | 2 | Mus musculus, Rattus norvegicus | T35 | VSLWETVQKWR | 1 | Homo sapiens | V30 | PQGATVSLWET | 1 | Homo sapiens | V30 | PQGTTVSLSET | 1 | Mus musculus | V30 | PQGATVSLSET | 1 | Rattus norvegicus | V36 | SLSETVQKWRE | 2 | Mus musculus, Rattus norvegicus | V36 | SLWETVQKWRE | 1 | Homo sapiens | W120 | NSSLPWRDLSE | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | W39 | ETVQKWREYRR | 2 | Homo sapiens, Mus musculus | W39 | ETVQKWREYRH | 1 | Rattus norvegicus | W91 | PWYLPWASSVL | 2 | Mus musculus, Rattus norvegicus | W91 | PWYLPWASSVP | 1 | Homo sapiens | Y101 | LQGHVYRFCTA | 2 | Mus musculus, Rattus norvegicus | Y101 | PQGHVYRFCTA | 1 | Homo sapiens | Y69 | RTFDDYACWPD | 2 | Mus musculus, Rattus norvegicus | Y69 | RTFDEYACWPD | 1 | Homo sapiens | Y88 | VSCPWYLPWAS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |